These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30744436)

  • 41. Pharmacokinetics and antitumor efficacy of DSPE-PEG2000 polymeric liposomes loaded with quercetin and temozolomide: Analysis of their effectiveness in enhancing the chemosensitization of drug-resistant glioma cells.
    Hu J; Wang J; Wang G; Yao Z; Dang X
    Int J Mol Med; 2016 Mar; 37(3):690-702. PubMed ID: 26782731
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
    Liu T; Li A; Xu Y; Xin Y
    Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma.
    Li Y; Zheng X; Gong M; Zhang J
    Oncotarget; 2016 Nov; 7(48):79401-79407. PubMed ID: 27765902
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
    Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
    Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
    [TBL] [Abstract][Full Text] [Related]  

  • 45. DMC is not better than TMZ on intracranial anti-glioma effects.
    Shi L; Sun G
    J Cell Biochem; 2018 Jul; 119(7):6057-6064. PubMed ID: 29575236
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
    Chaskis C; Neyns B; Michotte A; De Ridder M; Everaert H
    Surg Neurol; 2009 Oct; 72(4):423-8. PubMed ID: 19150114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
    Song S; Mao G; Du J; Zhu X
    Drug Deliv; 2016 May; 23(4):1404-8. PubMed ID: 26203687
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.
    Jaime-Ramirez AC; Dmitrieva N; Yoo JY; Banasavadi-Siddegowda Y; Zhang J; Relation T; Bolyard C; Wojton J; Kaur B
    J Gene Med; 2017 Mar; 19(3):. PubMed ID: 28087981
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy.
    Golden EB; Cho HY; Jahanian A; Hofman FM; Louie SG; Schönthal AH; Chen TC
    Neurosurg Focus; 2014 Dec; 37(6):E12. PubMed ID: 25434381
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Temozolomide Conjugated Carbon Quantum Dots Embedded in Core/Shell Nanofibers Prepared by Coaxial Electrospinning as an Implantable Delivery System for Cell Imaging and Sustained Drug Release.
    Shamsipour M; Mansouri AM; Moradipour P
    AAPS PharmSciTech; 2019 Jul; 20(7):259. PubMed ID: 31332574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting.
    Kuang Y; An S; Guo Y; Huang S; Shao K; Liu Y; Li J; Ma H; Jiang C
    Int J Pharm; 2013 Sep; 454(1):11-20. PubMed ID: 23867728
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
    Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
    J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells.
    Jiang G; Li R; Tang J; Ma Y; Hou X; Yang C; Guo W; Xin Y; Liu Y
    Oncol Rep; 2017 Feb; 37(2):995-1001. PubMed ID: 28035395
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation.
    Natsume A; Wakabayashi T; Ishii D; Maruta H; Fujii M; Shimato S; Ito M; Yoshida J
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):653-9. PubMed ID: 17564708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
    Kumthekar P; Grimm S; Chandler J; Mehta M; Marymont M; Levy R; Muro K; Helenowski I; McCarthy K; Fountas L; Raizer J
    J Neurooncol; 2017 Jul; 133(3):589-594. PubMed ID: 28510787
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma.
    Ling Y; Wei K; Zou F; Zhong S
    Int J Pharm; 2012 Jul; 430(1-2):266-75. PubMed ID: 22486964
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liposomal temozolomide drug delivery using convection enhanced delivery.
    Nordling-David MM; Yaffe R; Guez D; Meirow H; Last D; Grad E; Salomon S; Sharabi S; Levi-Kalisman Y; Golomb G; Mardor Y
    J Control Release; 2017 Sep; 261():138-146. PubMed ID: 28666727
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
    Kim JT; Kim JS; Ko KW; Kong DS; Kang CM; Kim MH; Son MJ; Song HS; Shin HJ; Lee DS; Eoh W; Nam DH
    Oncol Rep; 2006 Jul; 16(1):33-9. PubMed ID: 16786120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells.
    Kato T; Natsume A; Toda H; Iwamizu H; Sugita T; Hachisu R; Watanabe R; Yuki K; Motomura K; Bankiewicz K; Wakabayashi T
    Gene Ther; 2010 Nov; 17(11):1363-71. PubMed ID: 20520650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.